“Prokinetic” Treatment of Constipation-Predominant Irritable Bowel Syndrome

Outryve, M. Van; Milo, Ron; Toussaint, J; Eeghem, P Van

doi:10.1097/00004836-199102000-00012

Cited by 89 publications

(59 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This led to a marked increase in drug discovery and use. [20][21][22] Finally such a classification system provides legitimization for patients and doctors.…”

Section: Rationale For a Symptom-based Classificationmentioning

confidence: 99%

What Is New in Rome IV

Schmulson

Drossman

2017

J Neurogastroenterol Motil

604

431

View full text Add to dashboard Cite

Functional gastrointestinal disorders (FGIDs) are diagnosed and classified using the Rome criteria; the criteria may change over time as new scientific data emerge. The Rome IV was released in May 2016. The aim is to review the main changes in Rome IV. FGIDs are now called disorders of gut-brain interaction (DGBI). Rome IV has a multicultural rather than a Western-culture focus. There are new chapters including multicultural, age-gender-women's health, intestinal microenvironment, biopsychosocial, and centrally mediated disorders. New disorders have been included although not truly FGIDs, but fit the new definition of DGBI including opioidinduced gastrointestinal hyperalgesia, opioid-induced constipation, and cannabinoid hyperemesis. Also, new FGIDs based on available evidence including reflux hypersensitivity and centrally mediated abdominal pain syndrome. Using a normative survey to determine the frequency of normal bowel symptoms in the general population changes in the time frame for diagnosis were introduced. For irritable bowel syndrome (IBS) only pain is required and discomfort was eliminated because it is non-specific, having different meanings in different languages. Pain is now related to bowel movements rather than just improving with bowel movements (ie, can get worse with bowel movement).

show abstract

“…This led to a marked increase in drug discovery and use. [20][21][22] Finally such a classification system provides legitimization for patients and doctors.…”

Section: Rationale For a Symptom-based Classificationmentioning

confidence: 99%

What Is New in Rome IV

Schmulson

Drossman

2017

J Neurogastroenterol Motil

604

431

View full text Add to dashboard Cite

show abstract

“…24,32,[35][36][37]40,43,45,48,51,[53][54][55][56]59 Specific symptoms of constipation such as straining, passing hard stools, abdominal pain, and inability to defecate when desired were used as part of the entry criteria in nine trials involving 277 persons. 24,32,33,35,38,41,42,53,59 Whether the constipation was secondary to motility dysfunction or pelvic floor dysfunction was only stated in three trials. 31,32,38 One small trial involved 10 persons with pelvic floor dysfunction, 32 and two others involved 37 persons with motility dysfunction.…”

Section: Trial Participants and Settingsmentioning

confidence: 99%

The Treatment of Chronic Constipation in Adults A Systematic Review

et al. 1997

View full text Add to dashboard Cite

OBJECTIVE:To evaluate whether laxatives and fiber therapies improve symptoms and bowel movement frequency in adults with chronic constipation. CONCLUSIONS: Both fiber and laxatives modestly improved bowel movement frequency in adults with chronic constipation. There was inadequate evidence to establish whether fiber was superior to laxatives or one laxative class was superior to another. DATA SOURCES:

show abstract

“…In fact, cisapride improved mild to moderate constipation [67] but unfortunately is no longer available in the market. Tegaserod, another 5-HT 4 receptor agonist, was superior to placebo for the treatment of patients with chronic constipation in a large, randomized, double-blind, controlled trial [68].…”

Section: Treating Other Functional Bowel Disordersmentioning

confidence: 99%

Pharmacological Treatment of the Irritable Bowel Syndrome and Other Functional Bowel Disorders

Mearin

2006

Digestion

View full text Add to dashboard Cite

Functional digestive disorders constitute one of the main causes of consultation in gastroenterology and primary health care. Is still unclear whether therapy has to be aimed to the gut, to the neural pathways controlling bowel motility and perception, or to the processing mechanisms of symptoms and disease behaviour. It is conceivable that in the next future better understanding of functional bowel disorders pathophysiology will help us to tailor treatment for different patients. At the moment, subclassification of the diverse patterns of symptomatology allows to adjust new treatments for irritable bowel syndrome (IBS) according to the clinical predominance for each patient. The knowledge of motor and sensorial response to different stimuli in IBS patients and the pathways to the central nervous system is an important source of information for the development of new molecules. Fiber-enriched diet is frequently given for constipation-predominant IBS. Loperamide, antispasmodic drugs and tricyclic antidepressants are nowadays the basis for pharmacological treatment of diarrhea- predominant IBS. The scientific evidence supporting this therapeutical approach is however limited. Visceral analgesics and serotonin agonists and antagonists may play an important therapeutical role in the near future. However, it is not likely that one single treatment will help every functional bowel disorder patient and many of them will need a more complex approach with a multidisciplinary therapy (diet, psychotherapy, medications).

show abstract

“Prokinetic” Treatment of Constipation-Predominant Irritable Bowel Syndrome

Cited by 89 publications

References 0 publications

What Is New in Rome IV

What Is New in Rome IV

The Treatment of Chronic Constipation in Adults A Systematic Review

Pharmacological Treatment of the Irritable Bowel Syndrome and Other Functional Bowel Disorders

Contact Info

Product

Resources

About